Palbociclib or Ribociclib with Aromatase Inhibitor in Post-menopausal Women with ER+/HER2 – Advanced Breast Cancer? Real-world Overall Survival Evidence

Purpose: The CDK4/6 inhibitors, palbocilib [1] and ribociclib [2,3], have shown significant improvements in progression-free survival (PFS) in ER+/HER2 – advanced breast cancers. In the MONALEESA-2 trial, ribociclib showed a significant median overall survival (OS) of 63.9 months [4]. However, in the PALOMA-2 study [5], palbociclib showed a median OS of 53.9 months that was non-significant. The observed differences in OS have generated uncertaint y around which CDK4/6 inhibitor to choose in routine clinical practice.

Source: Clinical Oncology - May 6, 2023 Category: Radiology Authors: H.K.C. Tang, K. De Souza, O. Ahmad, T. Shafiq, S. Khan, A. Anand, S. Karim, S. Trivedi, E.A. Rahka, S. Madhusudan Source Type: research